-
US Stock Futures Signal Higher Start On Wall Street
Tuesday, May 31, 2011 - 6:29am | 381US stock futures are higher this morning after the Memorial Day holiday. Futures on the Dow Jones Industrial Average jumped 115 points to 12,543.00 and futures on the S&P 500 stock index rose 13.40 points to 1,343.40. Nasdaq 100 futures gained 25.75 points to 2,358.25. US markets were closed...
-
Stocks To Watch For May 31
Tuesday, May 31, 2011 - 1:01am | 220Some of the stocks that may grab investor focus today are: Wall Street expects Lions Gate Entertainment Corp (NYSE: LGF) to report its FQ4 EPS at $0.18 on revenue of $400.07 million. LGF shares gained 1.01% to $6.00 in after-hours trading. Optimer Pharmaceuticals Inc (NASDAQ: OPTR) reported that...
-
Data Mixed 05-27-2011
Friday, May 27, 2011 - 2:39pm | 942Cusick's Corner This is what I expected going into this long weekend -- a listless consolidated trade. I was not surprised the market was mute when the housing data came out. The market's reaction was one that could be expected since the Income and Spending numbers came in line which was huge. I...
-
Calls Purchased on Elan Corporation
Friday, May 27, 2011 - 1:32pm | 129Shares of Elan Corporation (NYSE: ELN) are higher on the session by 3.72%, currently trading at $9.48. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today. A...
-
Jefferies Maintains Buy on Amarin
Friday, May 27, 2011 - 9:14am | 89Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "The National Heart, Lung, and Blood Institute announced discontinuation of the AIM-HIGH trial, concluding that niacin with statin would not show benefit over statin alone in...
-
Morgan Stanley Gives Color on Johnson & Johnson's in Pharma Review
Friday, May 27, 2011 - 8:27am | 92According to a recent article from Morgan Stanley, Johnson & Johnson (NYSE: JNJ) has estimated a lead in the pharma industry for total drug sales launched in 2009- 11. JNJ reported these sales have totaled over $1.1 billion. In the report, Morgan Stanley said, "We expect this momentum to...
-
Morgan Stanley Reports on Merck
Friday, May 27, 2011 - 8:08am | 182Morgan Stanley commented on Merck (NYSE: MRK) in a report released yesterday. In the report, Morgan Stanley was neutral in its assessment of the company. Morgan Stanley writes, "AIM-HIGH trial's surprising failure raises risk that Cordaptive's HPS2-THRIVE trial may fail. Both the AIM-HIGH and HPS2...
-
UPDATE: J.P. Morgan Lowers PT on BioMimetic Therapeutics to $10
Friday, May 27, 2011 - 7:57am | 110J.P. Morgan is out with its report today on BioMimetic Therapeutics (NASDAQ: BMTI), lowering its PT from $17 to $10. In a note to clients, J.P. Morgan writes, "We value BioMimetic primarily on an EV/Sales basis, supported by DCF analysis. Because BMTI is an earlier-stage company than many of its...
-
Goldman Sachs Sees Johnson & Johnson As "Under-appreciated"
Friday, May 27, 2011 - 7:46am | 105According to Goldman Sachs, Johnson & Johnson's (NYSE: JNJ) Pharma Analyst Day reinforced Goldman's conviction in JNJ as the best new product story in the global drug sector, given its dominant positions in the largest and fastest growing categories. Goldman Sachs said that many of JNJ's new...
-
J.P. Morgan Comments on Johnson & Johnson's Reinvigorated Pipeline
Friday, May 27, 2011 - 7:41am | 85Johnson & Johnson (NYSE: JNJ) hosted an analyst meeting recently, which, according to J.P. Morgan, “highlights [a] reinvigorated pipeline.” “J&J hosted its bi-annual Pharmaceutical analyst meeting Thursday in New Brunswick,” J.P. Morgan writes. “At the meeting, management highlighted its...
-
Citi Maintains Buy on Endo Pharmaceuticals Holdings
Friday, May 27, 2011 - 7:24am | 164Citi is out with its report today on Endo Pharmaceuticals Holdings (NASDAQ: ENDP), maintaining Buy. In a note to clients, Citi writes, "We rate the shares of Endo as Buy/High Risk (1H). We expect Lidoderm and the Opana/Opana ER franchise to continue to generate material cash flows for several...
-
JP Morgan Lowers PT On BioMimetic Therapeutics To $10
Friday, May 27, 2011 - 6:58am | 27JP Morgan has lowered the price target on BioMemetic Therapeutics (NASDAQ: BMTI) from $17 to $10 and maintains its Overweight rating.
-
New pipeline boosts Sanofi-Aventis (SNY)
Thursday, May 26, 2011 - 8:00pm | 110by Paul Tracy, editor High Yield International Last year, Paris-based pharmaceutical giant Sanofi-Aventis (SNY) faced a problem many large pharmaceutical firms have encountered in recent years: a raft of major patent expirations. Now, however, growth from Sanofi's pipeline of new drugs is...
-
New pipeline boosts Sanofi-Aventis (SNY)
Thursday, May 26, 2011 - 8:00pm | 110by Paul Tracy, editor High Yield International Last year, Paris-based pharmaceutical giant Sanofi-Aventis (SNY) faced a problem many large pharmaceutical firms have encountered in recent years: a raft of major patent expirations. Now, however, growth from Sanofi's pipeline of new drugs is...
-
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX Orally Inhaled Migraine Drug
Thursday, May 26, 2011 - 4:31pm | 80MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation,...